[1] |
Guo Zehao, Zhang Junwang.
Role of PFDN and its subunits in tumorigenesis and tumor development
[J]. Journal of International Oncology, 2024, 51(6): 350-353.
|
[2] |
Gong Yan, Chen Honglei.
Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer
[J]. Journal of International Oncology, 2024, 51(3): 186-190.
|
[3] |
Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie.
Research progress of myeloid-derived suppressor cells in tumor angiogenesis
[J]. Journal of International Oncology, 2024, 51(1): 50-54.
|
[4] |
Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui.
Role of ABRACL in the occurrence and development of malignant tumors
[J]. Journal of International Oncology, 2023, 50(9): 544-547.
|
[5] |
Pan Shulan, Liu Chang, He Ping.
Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer
[J]. Journal of International Oncology, 2023, 50(8): 457-462.
|
[6] |
Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei.
Current status of research on exosomes in malignancies
[J]. Journal of International Oncology, 2023, 50(8): 484-488.
|
[7] |
An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.
Research progress of Nrf2 in ovarian cancer
[J]. Journal of International Oncology, 2023, 50(8): 493-497.
|
[8] |
Li Chenxi, Zhao Hongwei.
Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery
[J]. Journal of International Oncology, 2023, 50(6): 342-347.
|
[9] |
Yang Lirong, Wang Yufeng.
Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer
[J]. Journal of International Oncology, 2023, 50(4): 220-226.
|
[10] |
Liu Yujie, Zhao Zhiqiang, Wang Zicheng.
Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer
[J]. Journal of International Oncology, 2023, 50(12): 717-722.
|
[11] |
Deng Lili, Duan Xingyu, Li Baozhong.
Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma
[J]. Journal of International Oncology, 2023, 50(12): 751-757.
|
[12] |
Li Lixi, Wen Tingyu, Guan Xiuwen, Zhai Jingtong, Ma Fei.
Genetic susceptibility genes and clinical features of early-onset breast cancer
[J]. Journal of International Oncology, 2022, 49(4): 206-209.
|
[13] |
Yu Jiaojiao, Wang Jun, Wang Likang, Yao Nan.
Advances in the amplification of HER2 in metastatic colorectal cancer
[J]. Journal of International Oncology, 2021, 48(4): 246-249.
|
[14] |
Li Chenxi, Zhao Hongwei.
Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors
[J]. Journal of International Oncology, 2021, 48(3): 180-183.
|
[15] |
Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao.
GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway
[J]. Journal of International Oncology, 2021, 48(12): 716-722.
|